China Biotech Services Holdings (HKSE:08037) Total Receivables: HK$12.76 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08037 China Biotech Services Holdings Ltd HKSE:08037
19 GF Score
Price HK$0.64
GF Value HK$0.27
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is China Biotech Services Holdings Total Receivables?

China Biotech Services Holdings HKSE:08037 -1.54% 19 Total Receivables is HK$12.76 Mil as of Dec. 2025. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review.

China Biotech Services Holdings's Total Receivables for the quarter that ended in Dec. 2025 was HK$12.76 Mil.

China Biotech Services Holdings Total Receivables Related Terms

China Biotech Services Holdings Total Receivables Historical Data

* Premium members only.

The historical data trend for China Biotech Services Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Biotech Services Holdings Total Receivables Chart

China Biotech Services Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.20 773.18 30.56 21.05 12.76

China Biotech Services Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.56 23.74 21.05 16.26 12.76
HKSE:08037
19GF Score
China Biotech Services Holdings Ltd HKSE:08037
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Biotech Services Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$12.76 Mil mean?
China Biotech Services Holdings (HKSE:08037) has a Total Receivables of HK$12.76 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on China Biotech Services Holdings and its competitors.
Is China Biotech Services Holdings' Total Receivables too high?
China Biotech Services Holdings' current Total Receivables is HK$12.76 Mil. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Total Receivables compare to TMO and DHR?
China Biotech Services Holdings' Total Receivables of HK$12.76 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on China Biotech Services Holdings and its competitors. China Biotech Services Holdings's current Total Receivables is HK$12.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Total Receivables is HK$12.76 Mil. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Total Receivables is HK$12.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?

Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued. The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27. GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:08037:

  • Total Receivables: HK$12.76 Mil
  • GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
  • GF Score™: 19/100 with 6 warning signs

No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Biotech Services Holdings Business Description

Address 255-257 Gloucester Road, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score

Get the complete analysis for HKSE:08037

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.64
Price
HK$0.27
GF Value